Loading...
XSHE002728
Market cap647mUSD
Jan 10, Last price  
8.67CNY
1D
-6.67%
1Q
8.38%
Jan 2017
-54.75%
IPO
9.47%
Name

Teyi Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002728 chart
P/E
18.74
P/S
4.45
EPS
0.46
Div Yield, %
3.14%
Shrs. gr., 5y
10.52%
Rev. gr., 5y
3.82%
Revenues
1.07b
+20.38%
202,139,105250,807,519305,131,322340,827,193342,720,955344,748,357516,540,038655,856,830686,943,602884,975,624921,122,276632,695,186758,160,497886,570,9381,067,212,109
Net income
253m
+42.07%
24,099,88347,984,75169,694,93478,578,10480,554,67880,193,67381,105,34294,777,036106,342,795155,546,465171,710,43143,816,477126,917,422178,204,104253,175,789
CFO
199m
-46.58%
22,315,50146,915,76069,806,575104,502,75074,229,58857,348,29668,867,455101,296,691102,956,107187,969,540221,644,491168,985,866256,814,750371,658,160198,557,705
Dividend
Apr 24, 20240.7 CNY/sh
Earnings
Mar 28, 2025

Profile

Teyi Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical preparations, raw materials, and products in China. The company offers cough and phlegm, kidney, anti- infection, cardiovascular, and digestive system drugs. Its chemical raw materials and products include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co., Ltd. in November 2016. Teyi Pharmaceutical Group Co., Ltd. is based in Taishan, China.
URL
http://www.tczy.com.cn
IPO date
Jul 31, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,067,212
20.38%
886,571
16.94%
Cost of revenue
685,987
616,938
Unusual Expense (Income)
NOPBT
381,226
269,633
NOPBT Margin
35.72%
30.41%
Operating Taxes
39,818
18,121
Tax Rate
10.44%
6.72%
NOPAT
341,407
251,513
Net income
253,176
42.07%
178,204
40.41%
Dividends
(149,018)
Dividend yield
1.81%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
306,000
847,180
Long-term debt
38,585
Deferred revenue
18,511
Other long-term liabilities
20,769
(38,585)
Net debt
(364,375)
122,491
Cash flow
Cash from operating activities
198,558
371,658
CAPEX
(86,047)
Cash from investing activities
(85,531)
Cash from financing activities
(105,442)
FCF
133,004
298,180
Balance
Cash
647,247
739,660
Long term investments
23,128
23,614
Excess cash
617,015
718,946
Stockholders' equity
888,500
791,954
Invested Capital
1,720,437
1,526,760
ROIC
21.03%
16.21%
ROCE
16.20%
11.93%
EV
Common stock shares outstanding
460,320
311,857
Price
17.89
11.05%
16.11
31.73%
Market cap
8,235,118
63.91%
5,024,024
32.39%
EV
7,870,743
5,146,515
EBITDA
441,330
322,158
EV/EBITDA
17.83
15.98
Interest
16,365
29,133
Interest/NOPBT
4.29%
10.80%